STI571 (Imatinib Mesylate) Reduces Bone Marrow Cellularity and Normalizes Morphologic Features Irrespective of Cytogenetic Response

This publication has 18 references indexed in Scilit:

• Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
  New England Journal of Medicine, 2001
• Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
  Science, 2000
• Normal and chronic phase CML hematopoietic cells repopulate NOD/SCID bone marrow with different kinetics and cell lineage representation
  The Hematology Journal, 2000
• The tyrosine kinase inhibitor STI571, like interferon-α, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia
  Experimental Hematology, 2000
• Effects of interferon and hydroxyurea on bone marrow fibrosis in chronic myelogenous leukaemia: a comparative retrospective multicentre histological and clinical study
  British Journal of Haematology, 2000
• Interferon-α and Bcr-Abl Antisense Oligodeoxynucleotides in Combination Enhance the Antileukemic Effect and the Adherence of CML Progenitors to Preformed Stroma
  Leukemia & Lymphoma, 1999
• Inhibition of the ABL Kinase Activity Blocks the Proliferation of BCR/ABL+Leukemic Cells and Induces Apoptosis
  Blood Cells, Molecules, and Diseases, 1997
• Apoptosis and proliferation (PCNA labelling) in CML—a comparative immunohistological study on bone marrow biopsies following interferon and busulfan therapy
  The Journal of Pathology, 1997
• Increased growth and collagen synthesis of bone marrow fibroblasts from patients with chronic myelocytic leukaemia
  British Journal of Haematology, 1985
• Quantitation of Bone Marrow Reticulin—A Normal Range
  American Journal of Clinical Pathology, 1971